Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4700+0.0100 (+0.68%)
At close: 04:00PM EST
1.4800 +0.01 (+0.68%)
After hours: 07:31PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close1.4600
Open1.4400
Bid1.4500 x 1100
Ask1.4700 x 2200
Day's Range1.4200 - 1.4727
52 Week Range1.1800 - 3.9900
Volume124,731
Avg. Volume300,006
Market Cap55.362M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6360
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BOLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bolt Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • Simply Wall St.

    Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

    REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer

  • GlobeNewswire

    Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

    – BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022– BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022– Cash balance of $209.6 million anticipated to fund key milestones through 2025 REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results

Advertisement
Advertisement